ROIV
MaterialsRoivant Sciences Ltd
$28.82+0.50 (+1.77%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ROIV Today?
No stock-specific AI insight has been generated for ROIV yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$20.6B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume3.7M
Avg Volume (10D)—
Shares Outstanding715.7M
ROIV News
22 articles- Baron Fund Puts Spotlight On Roivant’s Brepocitinib And Valuation GapSimply Wall Street·May 8, 2026
- Here’s Why Roivant Sciences Ltd (ROIV) Rallied in Q1Yahoo Finance·May 4, 2026
- Piper Sandler and Bernstein Bullish on Roivant Sciences (ROIV)Yahoo Finance·Apr 30, 2026
- Roivant Sciences Ltd. (ROIV): David Einhorn Trims StakeYahoo Finance·Apr 29, 2026
- Roivant Sciences Ltd. (ROIV): One of the Best Stocks to Buy According to Joe EdelmanYahoo Finance·Apr 27, 2026
- Kodiak Sciences Inc (KOD): What’s the Chance of Success for Zenkuda?Yahoo Finance·Apr 23, 2026
- Arbutus Biopharma (ABUS) Wins FDA Fast Track for ImdusiranYahoo Finance·Apr 23, 2026
- Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 FailureYahoo Finance·Apr 15, 2026
- Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsightGlobeNewswire Inc.·Apr 15, 2026
- Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Apr 10, 2026
- This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.247 Wall St·Apr 3, 2026
- Should Brepocitinib’s New Trials and Batoclimab’s Setback Require Action From Roivant Sciences (ROIV) Investors?Yahoo Finance·Apr 3, 2026
- Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPPMarketbeat·Apr 2, 2026
- Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED EndpointMarketbeat·Apr 2, 2026
- Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)GlobeNewswire Inc.·Apr 2, 2026
- Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)Yahoo Finance·Apr 2, 2026
- New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in DermatomyositisGlobeNewswire Inc.·Mar 28, 2026
- Bernstein Initiates Coverage of Roivant Sciences Ltd. (ROIV) with an Outperform RatingYahoo Finance·Mar 25, 2026
- BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands NationwideMotley Fool·Mar 5, 2026
- Moderna Stock Pops After Inking $950 Million Covid Vaccine SettlementYahoo Finance·Mar 4, 2026
- A Look At Roivant Sciences (ROIV) Valuation After Recent Share Price StrengthYahoo Finance·Mar 4, 2026
- Moderna Settles a Covid Vaccine Patent Lawsuit. What It Means for the Stock.Yahoo Finance·Mar 4, 2026
All 22 articles loaded
Price Data
Open$28.64
Previous Close$28.32
Day High$29.00
Day Low$28.06
52 Week High—
52 Week Low—
Fundamentals
Market Cap$20.6B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume3.7M
Avg Volume (10D)—
Shares Outstanding715.7M
About Roivant Sciences Ltd
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—